Last reviewed · How we verify
URO-902
At a glance
| Generic name | URO-902 |
|---|---|
| Also known as | hMaxi-K, pVAX/hSlo |
| Sponsor | Urovant Sciences GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence (PHASE2)
- Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED (PHASE2)
- Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity (PHASE1)
- Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- URO-902 CI brief — competitive landscape report
- URO-902 updates RSS · CI watch RSS
- Urovant Sciences GmbH portfolio CI